Stockscreener 앱 받기
5.255
3.85%
0.195
전일 마감가:
$5.06
열려 있는:
$5.12
하루 거래량:
125.84K
Relative Volume:
0.26
시가총액:
$1.58B
수익:
$391.87M
순이익/손실:
$-441.45M
주가수익비율:
-2.8405
EPS:
-1.85
순현금흐름:
$-301.21M
1주 성능:
-4.28%
1개월 성능:
-38.32%
6개월 성능:
-48.28%
1년 성능:
-57.76%
1일 변동 폭
$5.065
$5.32
1주일 범위
$5.05
$5.49
52주 변동 폭
$4.70
$13.70
Alvotech Stock (ALVO) Company Profile
ALVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.255 | 1.58B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
120.78 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.8665 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.18 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
472.99 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Why Alvotech (ALVO) Is Down 7.8% After Surprising Full-Year Revenue Guidance Cut - simplywall.st
Alvotech and Advanz announce EC approval for Gobivaz biosimilar - Pharmaceutical Technology
Pomerantz Law Firm Investigates Claims On Behalf of Investors of AlvotechALVO - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AlvotechALVO - PR Newswire
Alvotech and Advanz win EC approval for first Simponi biosimilar - The Pharma Letter
Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar - TipRanks
Gobivaz approved across Europe as first Simponi biosimilar - PharmaTimes
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position - simplywall.st
Alvotech, Advanz Pharma secure European approval for Gobivaz, Simponi biosimilar - Seeking Alpha
European Commission approves Alvotech’s biosimilar golimumab - Investing.com India
European Commission approves Alvotech’s biosimilar golimumab By Investing.com - Investing.com Canada
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - The Manila Times
Will Alvotech (Z45) stock outperform foreign stocks2025 Short Interest & Fast Gaining Stock Reports - newser.com
Alvotech and Advanz Pharma Receive Marketing Approval - GlobeNewswire
Is Alvotech (Z45) stock attractive for growth fundsTrade Entry Report & AI Forecasted Stock Moves - newser.com
Can Alvotech (Z45) stock reach $200 price target2025 Technical Overview & Fast Momentum Entry Tips - newser.com
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent
What MACD signals say about Alvotech2025 Earnings Surprises & Weekly Return Optimization Alerts - newser.com
Using economic indicators to assess Alvotech Equity Warrant potentialJuly 2025 Summary & High Conviction Buy Zone Alerts - newser.com
Is Alvotech (Z45) stock good for long term investingWeekly Market Report & Fast Moving Stock Watchlists - newser.com
Is Alvotech stock a smart buy before Fed meetingPortfolio Risk Report & Smart Swing Trading Alerts - newser.com
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing - GlobeNewswire
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - GlobeNewswire Inc.
UBS Group Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
Can Alvotech Equity Warrant stock deliver surprise earnings beatWeekly Trend Recap & Technical Pattern Based Signals - newser.com
Alvotech (ALVO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
How analysts rate Alvotech stock todayWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
What technical patterns form on Alvotech (Z45) stock charts2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Will Alvotech Equity Warrant stock deliver shareholder valueLayoff News & Smart Investment Allocation Insights - newser.com
Trend analysis for Alvotech this weekWall Street Watch & Expert Verified Stock Movement Alerts - newser.com
UBS Maintains Alvotech (ALVO) Buy Recommendation - Nasdaq
Is Alvotech (Z45) stock a top dividend aristocrat candidateJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
UBS Maintains Buy Rating on ALVO, Lowers Price Target to $10.00 - GuruFocus
Alvotech at Jefferies London: Strategic Growth Amid Challenges By Investing.com - Investing.com India
Alvotech at Jefferies London: Strategic Growth Amid Challenges - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alvotech (ALVO) And Encourages Shareholders to Reach Out - ACCESS Newswire
UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating - MarketScreener
What hedge fund activity signals for Alvotech Equity Warrant stockOptions Play & Low Drawdown Investment Ideas - newser.com
ATTENTION ALVO Shareholders: Lost Money on Alvotech? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Alvotech (ALVO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals - TipRanks
Alvotech’s Earnings Call: Growth Amid Challenges - MSN
Will Alvotech stock reach all time highs in 2025July 2025 Update & Daily Entry Point Alerts - newser.com
Why Alvotech stock could outperform in 2025Quarterly Growth Report & Verified Trade Idea Suggestions - newser.com
Will Alvotech stock benefit from AI adoptionJuly 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
How Alvotech (Z45) stock trades under stagflationM&A Rumor & Safe Entry Zone Identification - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alvotech (ALVO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Alvotech (ICSE:ALVO) Price Target Decreased by 35.59% to 1,409.50 - Nasdaq
Applying chart zones and confluence areas to AlvotechJuly 2025 Review & Consistent Profit Trade Alerts - newser.com
Detecting price anomalies in Alvotech Equity Warrant with AIMarket Trend Summary & Community Verified Trade Signals - newser.com
Risk adjusted return profile for Alvotech analyzedTrade Volume Summary & Free Growth Oriented Trading Recommendations - newser.com
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.98%
0.39%
자본화:
|
볼륨(24시간):